Cytek Biosciences
United States
41 articles about Cytek Biosciences
-
Cytek Biosciences to Participate in the 44th Annual Goldman Sachs Healthcare Conference
5/31/2023
Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming 44th Annual Goldman Sachs Healthcare Conference in Dana Point, CA.
-
Cytek Biosciences Announces $50 Million Stock Repurchase Program
5/19/2023
Cytek Biosciences, Inc., a leading cell analysis solutions company, announced that its Board of Directors has approved the repurchase of up to an aggregate of $50 million of its common stock, subject to compliance with applicable law.
-
Cytek® Biosciences Marks Shipment of Its 100th Cell Sorter as the Company Continues to Lead Cell Analysis Forward
5/16/2023
Cytek Biosciences, Inc., a leading cell analysis solutions company, announced that it has shipped its 100thCytek Aurora CS system.
-
Cytek Biosciences Reports First Quarter 2023 Financial Results
5/9/2023
Cytek® Biosciences, Inc. reported financial results for the first quarter ended March 31, 2023.
-
Cytek Biosciences to Report First Quarter 2023 Financial Results on May 9, 2023
4/20/2023
Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the first quarter 2023 after market close on Tuesday, May 9th, 2023.
-
Cytek® Biosciences Introduces New 20-Color AML PanelOptimized for Cytek Cell Analysis Systems; Single-Tube Panel Accelerates Acute Myeloid Leukemia Research and MRD Detection
3/7/2023
Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the launch of a new 20-Color Acute Myeloid Leukemia (AML) Panel.
-
Sale of Flow Cytometry and Imaging Business From DiaSorin to Cytek® Biosciences Completed
2/28/2023
DiaSorin (FTSE MIB: DIA) and Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that Luminex Corporation, a wholly owned subsidiary of DiaSorin, has completed the sale of substantially all of its assets related to the Flow Cytometry & Imaging (FCI) business unit to Cytek for approximately USD 46.5 million.
-
Cytek Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results
2/28/2023
Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB) today reported financial results for the fourth quarter and year ended December 31, 2022.
-
Cytek® Biosciences to Acquire Flow Cytometry and Imaging Business from DiaSorin
2/13/2023
DiaSorin (FTSE MIB: DIA) and Cytek Biosciences, Inc.(Nasdaq: CTKB) today announced that Luminex Corporation, a wholly owned subsidiary of DiaSorin, has signed an agreement with Cytek to sell substantially all of its assets related to the Flow Cytometry & Imaging (FCI) business unit.
-
Cytek® Biosciences Partners with Bio-Rad to Expand Reagent PortfoliosNew Agreement Enhances High-Parameter Panels on Cytek Cell Analysis Systems
2/7/2023
Delivering a boost to immuno-oncology and immunotherapy researchers, Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that it has entered into a strategic partnership with leading life science research and clinical diagnostics products company Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb).
-
Cytek Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on February 28, 2023
2/7/2023
Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the fourth quarter and full year 2022 after market close on Tuesday, February 28th, 2023.
-
Cytek Biosciences to Participate in Upcoming Investor Conferences - February 06, 2023
2/6/2023
Cytek Biosciences, Inc., announced the company will be participating in the following investor conferences.
-
Cytek Biosciences to Participate in the Piper Sandler Healthcare Conference
11/21/2022
Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced the company will be participating in the upcoming Piper Sandler Healthcare Conference in New York, NY.
-
Cytek® Biosciences Introduces Cytek CloudNew Digital Ecosystem Supports Full Spectrum Flow Cytometry Research – from Panel Design to Data Acquisition
11/15/2022
Cytek Biosciences, Inc. announced the launch of Cytek Cloud – a cloud-based platform that features two integrated tools to streamline workflows on Cytek’s state-of-the-art cell sorters and analyzers.
-
Cytek Biosciences Reports Third Quarter 2022 Financial Results
11/9/2022
Cytek® Biosciences, Inc. reported financial results for the third quarter ended September 30, 2022.
-
The executive shuffle continues across the biopharma industry as companies shore up leadership needs with these Movers & Shakers.
-
Cytek® Biosciences Names Chris Williams Chief Operating Officer
10/31/2022
Cytek Biosciences, Inc. announced that Chris Williams has been appointed chief operating officer for the company.
-
Cytek to Participate in the 31st Annual Credit Suisse Healthcare Conference
10/26/2022
Cytek Biosciences, Inc., announced the company will be participating in the upcoming 31st Annual Credit Suisse Healthcare Conference in Rancho Palos Verdes, CA.
-
Cytek to Participate in the 20th Annual Morgan Stanley Global Healthcare Conference
8/30/2022
Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced the company will be participating in the upcoming 20th Annual Morgan Stanley Global Healthcare Conference in New York, NY.
-
Cytek Biosciences Reports Second Quarter 2022 Financial Results
8/10/2022
Cytek® Biosciences, Inc. reported financial results for the second quarter ended June 30, 2022.